Bradford Particle Design (bpd)
has been renamed Nektar Therapeutics. The change represents the refocus
of bpd's parent company Inhale, from inhalation drug delivery systems
to drug delivery by various routes, including oral, parenteral and inhalation.
The move follows the acquisitions
by Inhale of bpd and Shearwater.
Disclaimer: This
page may include links to information provided by external services
that are not in any way under the control of the University of Bradford.
The University cannot, therefore, be held responsible for its content
or accuracy.